O
4.69
0.50 (11.93%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Olema Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.9
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.88 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.32% |
| 机构持股比例 | 98.62% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Logos Global Management Lp | 31 Mar 2025 | 3,208,875 |
| Mpm Bioimpact Llc | 31 Mar 2025 | 2,930,446 |
| Lightspeed Management Company, L.L.C. | 31 Mar 2025 | 1,930,894 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 30.00 (HC Wainwright & Co., 539.66%) | 购买 |
| 中 | 25.00 (433.05%) | |
| 低 | 18.00 (Goldman Sachs, 283.80%) | 购买 |
| 平均值 | 24.50 (422.39%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 4.50 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 14 May 2025 | 18.00 (283.80%) | 购买 | 4.50 |
| Oppenheimer | 14 May 2025 | 22.00 (369.08%) | 购买 | 4.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 30.00 (539.66%) | 购买 | 4.89 |
| JP Morgan | 28 Mar 2025 | 28.00 (497.01%) | 购买 | 4.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合